New cocktail of three drugs shows promise for tough kidney cancers
NCT ID NCT07123090
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study is testing whether a combination of three drugs—sasanlimab, palbociclib, and axitinib—can shrink tumors or slow the growth of advanced kidney cancer. The trial will enroll 25 adults with clear cell or translocation renal cell carcinoma that has spread. Researchers will measure how many participants respond to treatment and track any serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sasanlimab, palbociclib, and axitinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced kidney cancer, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the combination may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?